Recent News

• 09.16.2025 - MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
• 09.12.2025 - MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation
• 08.19.2025 - MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage
• 08.12.2025 - MIRA Pharmaceuticals’ Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
• 07.30.2025 - MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study
• 07.29.2025 - MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain
• 07.11.2025 - MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

Recent Filings

• 09.15.2025 - 8-K Current report
• 09.11.2025 - 8-K Current report
• 09.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.19.2025 - 8-K Current report
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.12.2025 - 8-K Current report
• 08.08.2025 - DEFM14A Definitive proxy statement relating to merger or acquisition
• 08.08.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 07.29.2025 - 8-K Current report
• 07.29.2025 - PRER14A Preliminary Proxy Soliciting materials